Drugs · acquisition-cost intelligence
Carisoprodol Tablets, USP, 350 mg
carisoprodol· ingredient carisoprodol· CARISOPRODOL 250 mg/1; CARISOPRODOL 350 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.06572
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 8 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other carisoprodol products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| carisoprodol | $0.40890 | +$0.34320 |
Medicare Part D coverage · CY2026
On 84 plan formularies · typical tier 1
Prior auth 58% · Step therapy 0% · Quantity limit 55% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.